Nicole Forgione manages key relationships with industry and proposals for government funding at CCRM. A strong grounding in academic research helps her to understand the science behind new technologies in cell and gene therapy that CCRM is working to commercialize. Dr. Forgione obtained her Master’s degree from the University of Toronto (U of T) in the Department of Zoology and continued graduate studies at U of T in the Department of Cell and Systems Biology, where she completed a PhD in developmental neurobiology under the supervision of Dr. Vince Tropepe. Dr. Forgione went on to pursue studies in translational science with Dr. Michael Fehlings at the Krembil Research Institute in Toronto. Her post-doctoral work focused on animal models of spinal cord injury and cell based therapy for spinal cord regeneration. Nicole’s interest in science communication started early, with an undergraduate double major in English and Biology from Wilfrid Laurier University. Now she focuses her writing on anything and everything related to regenerative medicine technology. Follow Nicole on Twitter @DrNForgione.
Posts by: Nicole
One of my personal highlights from this year’s Till and McCulloch Meetings was attending the “Science for Citizens” panel (reported on in a previous post). Experts including Timothy Caulfield, patient advocate William Brock, and National Post writer Tom Blackwell emphasized the dangers of “fake news” in science and health care. I left that panel […]
Most people will tell you they hate networking. No matter how much we might dread awkward chit chat, networking and relationship building are key contributors to success, regardless of industry or job title. Because commercializing regenerative medicine (RM) technologies depends on collaboration across diverse sectors, relationship building is critical. With this in mind, RMConnectTO was […]
In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C>). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in […]
On November 28 local and international leaders of the regenerative medicine (RM) community gathered at the MaRS Centre in Toronto for the first ever Medicine by Design (MbD) Symposium. The event marked the first year of the MbD program at the University of Toronto (U of T). This initiative was established based on a $114 […]
A key driver for advancements in regenerative medicine is partnerships. In recognition of this, every year CCRM hosts a networking reception that brings together our partners for an evening of discussion and knowledge sharing. This year’s industry networking reception was focused on the theme of increasing partnerships between industry and academia. I had the privilege […]